Oxiconazole topical Pregnancy and Breastfeeding Warnings
Brand names: Oxistat
Medically reviewed by Drugs.com. Last updated on Aug 12, 2024.
Oxiconazole topical Pregnancy Warnings
This drug should be used during pregnancy only if clearly needed.
US FDA pregnancy category: B
Animal studies have failed to reveal evidence of fetal harm; rabbits, rats, and mice were administered oral doses up to 100, 150, and 200 mg/kg/day (57, 40, and 27 times the human dose based on mg/m2), respectively. There are no controlled data in human pregnancy.
US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
Oxiconazole topical Breastfeeding Warnings
Caution is recommended.
Excreted into human milk: Yes
Comments:
-The effects in the nursing infant are unknown; low risk is expected (less than 1% absorbed after topical use).
-Application to the nipple area should be avoided; the infant's skin should not come into direct contact with skin that has been treated.
See also
References for pregnancy information
- "Product Information. Oxistat (oxiconazole topical)." Glaxo Wellcome
References for breastfeeding information
- "Product Information. Oxistat (oxiconazole topical)." Glaxo Wellcome
- United States National Library of Medicine (2013) Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.